R
183.86
-4.21 (-2.24%)
| Previous Close | 188.07 |
| Open | 186.60 |
| Volume | 2,332,043 |
| Avg. Volume (3M) | 2,741,083 |
| Market Cap | 39,087,984,640 |
| Price / Sales | 9.04 |
| Price / Book | 26.58 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Diluted EPS (TTM) | -4.01 |
| Total Debt/Equity (MRQ) | 6.46% |
| Current Ratio (MRQ) | 13.46 |
| Operating Cash Flow (TTM) | -591.31 M |
| Levered Free Cash Flow (TTM) | -349.13 M |
| Return on Assets (TTM) | -23.09% |
| Return on Equity (TTM) | -36.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Revolution Medicines, Inc. | Mixed | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.33 |
|
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.02% |
| % Held by Institutions | 105.87% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |